BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33718145)

  • 1. A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution.
    Abedi AA; Grunnet K; Christensen IJ; Michaelsen SR; Muhic A; Møller S; Hasselbalch B; Poulsen HS; Urup T
    Front Oncol; 2021; 11():597587. PubMed ID: 33718145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
    Younis SG; Khedr RA; El-Shorbagy SH
    J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
    Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
    Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
    Bell EH; Pugh SL; McElroy JP; Gilbert MR; Mehta M; Klimowicz AC; Magliocco A; Bredel M; Robe P; Grosu AL; Stupp R; Curran W; Becker AP; Salavaggione AL; Barnholtz-Sloan JS; Aldape K; Blumenthal DT; Brown PD; Glass J; Souhami L; Lee RJ; Brachman D; Flickinger J; Won M; Chakravarti A
    JAMA Oncol; 2017 Jun; 3(6):784-792. PubMed ID: 28097324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
    Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
    Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
    Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R;
    Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of glioblastoma multiforme in elderly patients: treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival.
    Abhinav K; Aquilina K; Gbejuade H; La M; Hopkins K; Iyer V
    Clin Neurol Neurosurg; 2013 Aug; 115(8):1375-8. PubMed ID: 23333005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
    Lombardi G; Pace A; Pasqualetti F; Rizzato S; Faedi M; Anghileri E; Nicolotto E; Bazzoli E; Bellu L; Villani V; Fabi A; Ferrazza P; Gurrieri L; Dall'Agata M; Eoli M; Della Puppa A; Pambuku A; D'Avella D; Berti F; Rudà R; Zagonel V
    J Neurooncol; 2015 Nov; 125(2):359-67. PubMed ID: 26423801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location.
    Woo P; Ho J; Lam S; Ma E; Chan D; Wong WK; Mak C; Lee M; Wong ST; Chan KY; Poon WS
    World Neurosurg; 2018 Jul; 115():e375-e385. PubMed ID: 29678708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
    Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
    J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
    Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
    J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
    Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
    Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power.
    Franceschi E; Tosoni A; Minichillo S; Depenni R; Paccapelo A; Bartolini S; Michiara M; Pavesi G; Urbini B; Crisi G; Cavallo MA; Tosatto L; Dazzi C; Biasini C; Pasini G; Balestrini D; Zanelli F; Ramponi V; Fioravanti A; Giombelli E; De Biase D; Baruzzi A; Brandes AA;
    World Neurosurg; 2018 Apr; 112():e342-e347. PubMed ID: 29337169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
    Kim YH; Kim T; Joo JD; Han JH; Kim YJ; Kim IA; Yun CH; Kim CY
    Cancer; 2015 Sep; 121(17):2926-32. PubMed ID: 25975354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
    Thon N; Thorsteinsdottir J; Eigenbrod S; Schüller U; Lutz J; Kreth S; Belka C; Tonn JC; Niyazi M; Kreth FW
    J Neurol; 2017 Feb; 264(2):350-358. PubMed ID: 27921166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.